Vera Therapeutics (VERA) Share-based Compensation (2020 - 2026)

Vera Therapeutics has reported Share-based Compensation for 7 years, with the latest figure at $13.2 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 70.56% year-over-year to $13.2 million; the trailing twelve-month figure through Mar 2026 stood at $43.4 million (up 77.67% YoY), and the FY2025 full-year result was $37.9 million, up 82.32% from the prior year.
• Share-based Compensation for Q1 2026 stood at $13.2 million, up from $11.0 million in the prior quarter.
• The five-year high for Share-based Compensation was $13.2 million in Q1 2026, with the low at $1.7 million in Q1 2022.
• Historically, Share-based Compensation has averaged $5.4 million across 5 years, with a median of $4.1 million in 2024.
• Annual changes were most pronounced in 2022 — Share-based Compensation soared 311.39% — and 2023, when it climbed 17.21%.
• Vera Therapeutics' Share-based Compensation stood at $2.7 million in 2022, then climbed by 17.21% to $3.2 million in 2023, then jumped by 93.01% to $6.2 million in 2024, then jumped by 76.37% to $11.0 million in 2025, then advanced by 20.46% to $13.2 million in 2026.
• The last three Share-based Compensation figures came in at $13.2 million (Q1 2026), $11.0 million (Q4 2025), and $9.7 million (Q3 2025), per Business Quant data.